Market capitalization | $201.38m |
Enterprise Value | $215.52m |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.12 |
P/S ratio (TTM) P/S ratio | 2.92 |
P/B ratio (TTM) P/B ratio | 14.02 |
Sales growth (TTM) Sales growth | 42.07% |
Turnover (TTM) Turnover | $69.07m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
7 Analysts have issued a NeuroPace Inc forecast:
7 Analysts have issued a NeuroPace Inc forecast:
Mar '24 | |
Current assets | 84 84 |
Fixed assets | 15 15 |
Total assets | 99 99 |
Mar '24 | |
Equity | 14 14 |
Debt capital | 85 85 |
Total capital | 99 99 |
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.
Head office | United States |
CEO | Joel Becker |
Employees | 171 |
Founded | 1997 |
Website | www.neuropace.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.